Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction release_pav4kjdywvazdg2wso4x7n4oae

by Liyun Zhang, Juan Chen, Lianhua Yan, Qin He, Han Xie, Manhua Chen

Published in Frontiers in Pharmacology by Frontiers Media SA.

2021   Volume 12, p646240

Abstract

<jats:bold>Objective:</jats:bold> Accumulating evidence suggested that resveratrol (RES) could protect against adverse cardiac remodeling induced by several cardiovascular diseases. However, the role of RES in the setting of heart failure with preserved ejection fraction (HFpEF) and the underlying mechanisms of its action remain understood. This study was to determine whether RES could ameliorate HFpEF-induced cardiac remodeling and its mechanisms.<jats:bold>Methods:</jats:bold><jats:italic>In vivo</jats:italic>, C57BL/6 mice served as either the sham or the HFpEF model. The HFpEF mice model was induced by uninephrectomy surgery and d-aldosterone infusion. RES (10 mg/kg/day, ig) or saline was administered to the mice for four weeks. <jats:italic>In vitro</jats:italic>, transforming growth factor β1 (TGF-β1) was used to stimulate neonatal rat cardiac fibroblasts (CFs) and Ex-527 was used to inhibit sirtuin 1 (Sirt1) in CFs. Echocardiography, hemodynamics, western blotting, quantitative real-time PCR, histological analysis, immunofluorescence, and ELISA kits were used to evaluate cardiac remodeling induced by HFpEF. Sirt1 and Smad3 expressions were measured to explore the underlying mechanisms of RES.<jats:bold>Results:</jats:bold> HFpEF mice developed left ventricular hypertrophy, preserved ejection fraction, diastolic dysfunction, and pulmonary congestion. Moreover, HFpEF mice showed increased infiltration of neutrophils and macrophages into the heart, including increased interleukin (IL)-1β, IL-6, and TNF-α. We also observed elevated M1 macrophages and decreased M2 macrophages, which were exhibited by increased mRNA expression of M1 markers (iNOS, CD86, and CD80) and decreased mRNA expression of M2 markers (Arg1, CD163, and CD206) in HFpEF hearts. Moreover, HFpEF hearts showed increased levels of intracellular reactive oxygen species (ROS). Importantly, HFpEF mice depicted increased <jats:italic>collagen-I</jats:italic> and <jats:italic>-III</jats:italic> and TGF-β mRNA expressions and decreased protein expression of phosphorylated endothelial nitric-oxide synthase (p-eNOS). Results of western blot revealed that the activated TGF-β/Smad3 signaling pathway mediated HFpEF-induced cardiac remodeling. As expected, this HFpEF-induced cardiac remodeling was reversed when treated with RES. RES significantly decreased Smad3 acetylation and inhibited Smad3 transcriptional activity induced by HFpEF <jats:italic>via</jats:italic> activating Sirt1. Inhibited Sirt1 with Ex-527 increased Smad3 acetylation, enhanced Smad3 transcriptional activity, and offset the protective effect of RES on TGF-β–induced cardiac fibroblast–myofibroblast transformation in CFs.<jats:bold>Conclusion:</jats:bold> Our results suggested that RES exerts a protective action against HFpEF-induced adverse cardiac remodeling by decreasing Smad3 acetylation and transcriptional activity <jats:italic>via</jats:italic> activating Sirt1. RES is expected to be a novel therapy option for HFpEF patients.
In application/xml+jats format

Archived Files and Locations

application/pdf  3.0 MB
file_aerd5hjldzhx5bnr7mjtyaz64y
fjfsdata01prod.blob.core.windows.net (publisher)
web.archive.org (webarchive)
application/pdf  3.0 MB
file_q7oxxqfnq5h7zo7czors5fxdra
fjfsdata01prod.blob.core.windows.net (web)
web.archive.org (webarchive)

Web Captures

https://www.frontiersin.org/articles/10.3389/fphar.2021.646240/full
2022-06-16 16:18:39 | 36 resources
webcapture_vmjrsgpklvfobfipbeiterjyyy
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2021-06-10
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  1663-9812
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: d4cf26ef-c07a-4508-a9d0-d8bdb3be819b
API URL: JSON